ACCELERATE SPEED TO CLINIC, REDUCE PATIENT WAIT TIMES
Immunotherapies offer hope to cure patients in need, and it’s time to deliver a better manufacturing outcome for these life-saving therapies. As you navigate the journey to get to clinical trials for your cell therapy, you need a partner you can trust to guide you through the complex regulatory landscape, to increase the manufacturability of your therapy, and ultimately, to secure your path to commercialization and get it in the hands of those in need.
FROM PROJECT INITIATION TO CLINICAL READINESS IN UNDER 12 MONTHS
The Auto-T cell therapy manufacturing platform from Resilience offers therapeutic innovators a vetted and accelerated pathway to clinical trials. Auto-T is an end-to-end manufacturing and assay platform for LVV-based autologous CAR-T and TCR-T cell therapies containing all required regulatory support to get your clinical trial started within one year of signing on. Gain access to a platform that is well characterized with all release testing performed in-house for maximum efficiency. Auto-T accelerates your time to clinical readiness and gets your cell therapy innovation to patients faster.
All development, manufacturing and testing/quality operations take place inside our 85,000 sq. ft. Center of Excellence for Cellular Immunotherapy located outside of Philadelphia, PA. As your trusted cell therapy CDMO partner, Resilience is giving you access to the most advanced technologies to build a resilient tomorrow, today.
AUTO-T PLATFORM HIGHLIGHTS
Speed to Clinical Trial
Auto-T can get you from project initiation to clinical readiness in under one year
Consistent Performance Profile
Performs consistently with various vectors, constructs, and payload sizes to meet your needs
Regulatory Expertise
Processes and analytics are fully developed and vetted. Featured in multiple Investigational New Drug (IND) applications
Digitally Enabled
De-risk manufacturing and accelerate release timelines with paperless manufacturing
Modular and Flexible
Modifiable unit operations to adapt to your product specific needs, including different vectors and gene editing technologies
Transparent Terms
Terms are discussed up-front with no hidden catches to maximize efficiency and transparency
LET'S TALK CELL THERAPY. AND YOUR SUCESS.
Is your current program a good fit for Auto-T? Let’s connect and talk more about what’s driving your needs, objectives, and project dynamics.
